InSphero acquired PhenoVista Biosciences, expanding its cell-based assay services portfolio for drug development across oncology, fibrosis, and safety assessment. The transaction grants InSphero additional high-content imaging and phenotypic assay capabilities, and it is expected to support growth in neuroscience and neurotoxicity testing while increasing InSphero’s U.S. footprint.